Letter | Published:

Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth

Naturevolume 274pages798800 (1978) | Download Citation

Subjects

Abstract

THE interferons were originally described as proteins, produced by cells in response to virus infection, which could induce viral resistance in cells of the same species1. It is becoming clear that these proteins have other important biological activities2 and can inhibit cell division in both normal and malignant cells3–5. Although the phenomenon of growth inhibition by interferon is well established, data analysis of the effect in terms of the cell cycle is limited and not completely consistent. Killander et al.6 and Matarese and Rossi7, using asynchronously growing cultures of L1210 and Friend leukaemia cells respectively, have found that interferon-treated cells are delayed in both G1 and G2, and we have recently observed a similar effect of interferon on asynchronously growing MCF-7 cells8. Sokawa et al. have reported, however, that the only parameter affected in interferon-treated quiescent BALB/c 3T3 cells after serum stimulation, is their rate of entry into S (ref. 9). It is possible that the effect of interferon on the cell cycle of asynchronous transformed cells is different, in terms of cell cycle parameters, from its effect on quiescent untransformed cells. In an attempt to clarify this point, we have examined in detail the effect of interferon on the passage of serum-stimulated cells through the cell cycle, using BALB/c 3T3 and Swiss 3T3K cells, and a strain of human embryo lung diploid fibroblasts, HEL 27. In contrast to Sokawa et al., we have found that both G1 and S+G2 are extended by interferon treatment of all three cell types studied.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Isaacs, A. & Lindenmann, J. Proc. R. Soc. B 147, 258–267 (1957).

  2. 2

    Gresser, I. Cell. Immun. 34, 406–415 (1977).

  3. 3

    Paucker, K., Cantell, K. & Henle, W. Virology 17, 324–334 (1962).

  4. 4

    Balkwill, F. R. & Oliver, R. T. D. Int. J. Cancer 20, 500–505 (1977).

  5. 5

    Strander, H. & Einhorn, S. Int. J. Cancer 19, 468–473 (1977).

  6. 6

    Killander, D., Lindahl, P., Lundin, L., Leary, P. & Gresser, I. Eur. J. Immun. 6, 56–59 (1976).

  7. 7

    Matarese, G. & Rossi, G. J. Cell Biol. 75, 344–354 (1977).

  8. 8

    Balkwill, F., Watling, D. & Taylor-Papadimitriou, J. Int. J. Cancer (in the press).

  9. 9

    Sokawa, Y., Watanabe, Y., Watanabe, Y. & Kawade, Y. Nature 268, 236–238 (1977).

  10. 10

    Smith, J. & Martin, L. Proc. natn. Acad. Sci. U.S.A. 70, 1263–1267 (1973).

  11. 11

    Taylor-Papadimitriou, J., Stoker, M. & Riddle, P. Int. J. Cancer 7, 269–276 (1971).

  12. 12

    Havell, E. A., Yip, J. K. & Vilcek, J. J. gen. Virol. 38, 51–59 (1977).

Download references

Author information

Affiliations

  1. Imperial Cancer Research Fund, Lincoln's Inn Fields, London, WC2, UK

    • F. BALKWILL
    •  & J. TAYLOR-PAPADIMITRIOU

Authors

  1. Search for F. BALKWILL in:

  2. Search for J. TAYLOR-PAPADIMITRIOU in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/274798a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.